Absci Corp — Investor Relations & Filings
Filings indexed
315
across all filing types
Latest filing
2026-04-22
Annual Report
Country
US
United States of America
Listing
US
ABSI
Absci Corp. is a generative AI drug creation company focused on developing biologic medicines. The company's Integrated Drug Creation Platform combines artificial intelligence with scalable wet lab technologies to design and validate novel therapeutics. This platform operates through iterative cycles of data generation, AI model training, de novo design of biologics like antibodies, and experimental validation. Absci's capabilities also include AI-enabled target discovery using a proprietary 'Reverse Immunology' approach. As a clinical-stage company, it advances an internal pipeline and collaborates with pharmaceutical partners to accelerate the development of differentiated biologics for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | |
| SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | |
| S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | |
| 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 35398073 | ARS - Absci Corp (0001672688) (Filer) | 2026-04-22 | English | ||
| 33052408 | SCHEDULE 13D/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33048944 | SCHEDULE 13G/A - Absci Corp (0001672688) (Subject) | 2026-03-26 | English | ||
| 33035253 | S-8 - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 33035179 | 10-K - Absci Corp (0001672688) (Filer) | 2026-03-24 | English | ||
| 32896336 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896337 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-03-03 | English | ||
| 32896338 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-25 | English | ||
| 32896339 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 32896340 | 4 - ABSCI CORP (0001672688) (Filer) | 2026-02-04 | English | ||
| 31233301 | 4 Filing | 2026-02-04 | English | ||
| 31233143 | 4 Filing | 2026-02-04 | English | ||
| 31233276 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31233114 | 4 Filing | 2026-01-30 | English | ||
| 12952145 | 8-K | 2026-01-14 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CHIMERIC THERAPEUTICS LIMITED
Clinical-stage cell therapy company developing CAR T and NK…
|
CHM | AU | Professional, scientific and te… |
|
China National Electric Apparatus Research Institute Co., Ltd.
R&D institution for electrical and electronics testing, equ…
|
688128 | CN | Professional, scientific and te… |
|
Chiome Bioscience Inc.
Clinical-stage biotech company developing antibody-based th…
|
4583 | JP | Professional, scientific and te… |
|
CHITOGENX INC
Clinical stage regenerative medicine company focused on nov…
|
CHGX | CA | Professional, scientific and te… |
|
Chordate Medical Holding AB
Develops a patented, drug-free neuromodulation treatment fo…
|
CMH | SE | Professional, scientific and te… |
|
Chordia Therapeutics,Inc
Clinical-stage biotech developing novel cancer therapies ta…
|
190A | JP | Professional, scientific and te… |
|
Cibus, Inc.
Develops and licenses plant traits using non-GMO precision …
|
CBUS | US | Professional, scientific and te… |
|
Circio Holding ASA
Clinical-stage company developing circular RNA medicines an…
|
CRNA | NO | Professional, scientific and te… |
|
CIZZLE BIOTECHNOLOGY HOLDINGS PLC
A cancer diagnostics developer creating a blood test for ea…
|
CIZ | GB | Professional, scientific and te… |
|
CJ Bioscience
Develops microbiome therapeutics for oncology and IBD using…
|
311690 | KR | Professional, scientific and te… |
Absci Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32931/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32931 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32931 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32931 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32931}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Absci Corp (id: 32931)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.